BridgeBio Pharma, Inc.
BBIO
$76.08
$1.321.77%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 25.27% | 26.16% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 25.27% | 26.16% | |||
| Cost of Revenue | 51.38% | 22.60% | |||
| Gross Profit | 23.87% | 26.36% | |||
| SG&A Expenses | 13.65% | 3.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.74% | 6.32% | |||
| Operating Income | -1.06% | 17.50% | |||
| Income Before Tax | 6.40% | 14.48% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.40% | 14.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 46.30% | 41.76% | |||
| Net Income | 7.21% | 14.94% | |||
| EBIT | -1.06% | 17.50% | |||
| EBITDA | -1.20% | 17.50% | |||
| EPS Basic | 7.68% | 15.48% | |||
| Normalized Basic EPS | 8.17% | 10.67% | |||
| EPS Diluted | 7.68% | 15.48% | |||
| Normalized Diluted EPS | 8.17% | 10.67% | |||
| Average Basic Shares Outstanding | 0.51% | 0.64% | |||
| Average Diluted Shares Outstanding | 0.51% | 0.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||